A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction
ConclusionsEmpagliflozin added to SoC leads to health benefits for patients with HFrEF and is a cost-effective treatment option for payers in multiple European countries (UK, Spain, France).
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
More News: Cardiology | Cardiomyopathy | Databases & Libraries | Economics | Empagliflozin | France Health | Health Management | Heart | Heart Failure | Jardiance | Spain Health